From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
SH2B2 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2b3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sh2b3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2b3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sh2b3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B1 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B3 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D2A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2d1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sh2d1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2d1a Rat Pre-designed siRNA Set A contains three designed siRNAs for Sh2d1a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D4A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D4A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1B Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D3C Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D3C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Grb2SH2 domain inhibitor 1 is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
Grb2SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a Kd value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer .
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains [2].
N-Acetyl-O-phosphono-Tyr-Glu dipentylamide (Ac-Tyr-Glu-N(n-C5H11)2), a dipeptide, is a pp60 c-srcSH2 domain inhibitor. N-Acetyl-O-phosphono-Tyr-Glu dipentylamide can be used for cancer research .
STAT6-IN-3 is a phosphopeptide mimic targeting the SH2 domain of STAT6 and has a high affinity for STAT6 (IC50: 0.04 μM). STAT6-IN-3 can be used in the research of inflammation such as asthma .
Syk-IN-6 is an inhibitor of the lipid-SH2 domain interaction, control the cellular activity of kinases containing SH2 domain. Syk-IN-6 blocks Syk kinase activity, which associated hematopoietic malignancies, including acute myeloid leukemia (AML) .
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727) . Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3 [2]. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for src SH3-SH2:phosphoprotein interactions .
STAT3-IN-35 is a STAT3 inhibitor that binds to SH2 domain. STAT3-IN-35 inhibits the phosphorylation of STAT3 and possesses antiproliferative activities against triple-negative breast cancer (TNBC) cell lines. STAT3-IN-35 also has a toxicity and potent antitumor activity in a TNBC xenograft model .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for src SH3-SH2:phosphoprotein interactions .
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
pYEEI is a phosphotyrosine-containing tetrapeptide binds to Src SH2 domain with the Kd of 100 nM and with the IC50 of 6.5 μM. pYEEI plays an important role in cancer research .
Stattic (Standard) is the analytical standard of Stattic. This product is intended for research and analytical applications. Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727) . Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3 [2]. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice .
5,15-Diphenylporphyrin (5,15-DPP) is an inhibitor of the oncogenic transcription factor STAT3. 5,15-Diphenylporphyrin specifically binds to the SH2 domain of STAT3, blocking the pTyr-SH2 interaction, thereby inhibiting the dimerization, nuclear translocation and DNA binding activity of STAT3, and ultimately inhibiting the expression of cancer cell-related genes. 5,15-Diphenylporphyrin can be used in research fields related to the development of anticancer drugs[1][2].
STAT3-IN-13 (compound 6f) is a potent STAT3 inhibitor. STAT3-IN-13 has anti-proliferative effects and binds to the STAT3 SH2 domain with a KD of 0.46 μM. STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705 and downstream target gene expression. STAT3-IN-13 induces apoptosis in vitro and suppresses the growth and metastasis of tumor in vivo. STAT3-IN-13 can be used for cancer research .
AP22408 is a nonpeptide inhibitor against Src SH2 with an IC50 value of 0.3 μM. AP22408 inhibits rabbit osteoclast-mediated resorption of dentine, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model. AP22408 is proming for rasearch of osteoporosis and other bone-related diseases such as Paget’s disease, osteolytic bone metastasis and hypercalcemia associated with malignancy .
ZAP-180013 is a zeta-chain-associated protein kinase 70 (ZAP-70) inhibitor with an IC50 of 1.8 μM. ZAP-180013 inhibits the interaction of ZAP-70SH2 domain with immunoreceptor tyrosine-based activation motif (ITAMs) .
G7-18NATE is a peptide inhibitor of Grb7. HY-P10224 binds to the Grb7-SH2 domain with micromolar affinity (KD = 18.1 μM). G7-18NATE inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines [2].
PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. PM-81I can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer [1].
G7-18NATE TFA is a peptide inhibitor of Grb7. G7-18NATE TFA binds to the Grb7-SH2 domain with micromolar affinity (Kd = 18.1 μM). G7-18NATE TFA inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines [2].
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML) .
STAT6-IN-1 (Compound 19a) is a STAT6 inhibitor with a high affinity for the SH2 domain of STAT6 (IC50=0.028 µM). STAT6-IN-1 can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer [2] .
SI-109 is a potent STAT3 SH2 domain inhibitor (Ki=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC50=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader SD-36 .
STAT3-IN-38 (Compound 4m) is an inhibitor of STAT3 (KD of rhSTAT3: 45.33 µM). STAT3-IN-38 binds to the SH2 domain of STAT3 protein and suppresses the STAT3’s phosphorylation at site pTyr705 as well as its downstream genes (Survivin and Mcl-1). STAT3-IN-38 could block cell-cycle and induce Apoptosis in colorectal cancer cells .
STAT3-IN-32 (compound 2p) is an orally active, potent STAT3 dual phosphorylation inhibitor with an indole-containing tetra-aromatic heterocycle scaffold. STAT3-IN-32 exhibits STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 5.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 4.2 nM. STAT3-IN-32 significantly blocks p-Tyr705 and p-Ser727 and causes the abrogation of the corresponding nuclear transcription and mitochondrial oxidative phosphorylation functions of STAT3 by targeting the STAT3 SH2 domain (KD=21.3 nM). STAT3-IN-32 exhibits significant suppressive effects in a pancreatic cancer xenograft model .
C188 (CPD188) is a STAT3 inhibitor with anticancer effects. C188 inhibits STAT3 SH2/pY-peptide binding (IC50 of 20 µM against pY-peptide binding) and IL-6-mediated STAT3 phosphorylation. C188 is selective for STAT3 over STAT1. C188 inhibits nuclear-to-cytoplasmic translocation of Stat3. C188 shows highly active induces apoptosis in breast cancer cell lines with constitutive Stat3 activation (EC50s of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively) .
Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC50 values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research .
5-FAM-GpYLPQTV-NH2 (TFA) is a fluorescently labeled peptide and has STAT3 inhibitory activity. 5-FAM-GpYLPQTV-NH2 (TFA) can be used in cancer research .
Erasin is a potent Erlotinib (HY-50896)-resistance antagonizing STAT3 inhibitor with IC50s of 9.7 and 24 μM against STAT3 and STAT1, respectively. Erasin induces cancer cells apoptosis .
SD-36 is a potent and efficacious STAT3 PROTAC degrader (Kd=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC50=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase . SD-36 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
STAT3-IN-25 (Compound 2p) is a potent STAT3 inhibitor with a p-trifluoroethoxy benzyl substituent. STAT3-IN-25 shows STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 22.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 32.5 nM. STAT3-IN-25 has the potential for pancreatic cancer research .
Grb2SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains [2].
740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
Grb2SH2 domain inhibitor 1 is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for src SH3-SH2:phosphoprotein interactions .
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for src SH3-SH2:phosphoprotein interactions .
pYEEI is a phosphotyrosine-containing tetrapeptide binds to Src SH2 domain with the Kd of 100 nM and with the IC50 of 6.5 μM. pYEEI plays an important role in cancer research .
IRS1-derived peptide is a biological active peptide. (This is a peptide fragment (979-989) of the insulin receptor substrate-1 containing the sequence motif YMXM known to bind to the two domains of SH2 on the 85kDa subunit of phosphoinositide 3-kinase.)
G7-18NATE is a peptide inhibitor of Grb7. HY-P10224 binds to the Grb7-SH2 domain with micromolar affinity (KD = 18.1 μM). G7-18NATE inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines [2].
G7-18NATE TFA is a peptide inhibitor of Grb7. G7-18NATE TFA binds to the Grb7-SH2 domain with micromolar affinity (Kd = 18.1 μM). G7-18NATE TFA inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines [2].
5-FAM-GpYLPQTV-NH2 (TFA) is a fluorescently labeled peptide and has STAT3 inhibitory activity. 5-FAM-GpYLPQTV-NH2 (TFA) can be used in cancer research .
SH2D1A protein regulates receptors of the SLAM family (SLAMF1, CD244, LY9, CD84, SLAMF6, and SLAMF7). SH2D1A Protein, Human (His) is the recombinant human-derived SH2D1A protein, expressed by E. coli , with N-6*His labeled tag.
The SLP-76 protein is critical in T cell antigen receptor-mediated signaling and participates in multiple molecular interactions. Its association with SLA coordinates T cell signaling, whereas its interaction with CBLB emphasizes regulatory effects. SLP-76 Protein, Human (His-T7) is the recombinant human-derived SLP-76 protein, expressed by E. coli , with N-T7, C-6*His labeled tag.
Grb2, an adapter protein, crucially connects cell surface growth factor receptors to the Ras signaling pathway. Despite no direct binding to phosphorylated EGFR, Grb2 inhibits EGF-induced transactivation of a RAS-responsive element. It acts as a dominant negative relative to GRB2, suppressing proliferative signals and potentially initiating programmed cell death. Grb2 Protein, Human (His) is the recombinant human-derived Grb2 protein, expressed by E. coli , with C-6*His labeled tag.
CISH 1; CISH1; Cytokine inducible SH2 protein 1; JAB; JAK binding protein; JAK-binding protein; Janus kinase binding protein ; SOCS 1; TEC interacting protein 3; Tec-interacting protein 3; TIP 3
The SOCS1 protein is an important negative regulator that inhibits type I and type II interferon signaling as well as cytokines such as IL2, IL4, IL6, and LIF. It downregulates the signaling of the JAK/STAT pathway by inhibiting JAK proteins and IFNGR1. SOCS1 Protein, Human (P.pastoris, His) is the recombinant human-derived SOCS1 protein, expressed by P. pastoris , with N-His labeled tag.
NCK1 protein is an adapter protein that binds to tyrosine phosphorylated receptors (KDR, PDGFRB) and cellular substrates and plays a key role in the dephosphorylation of EIF2S1 by PP1. It contributes to the efficient activation of DNA damage response effector (CHEK2) and ELK1-dependent transcriptional activation in Ras signaling. NCK1 Protein, Human (His) is the recombinant human-derived NCK1 protein, expressed by E. coli , with N-6*His labeled tag.
SHC1; SHC; SHCA; SHC-transforming protein 1; SHC-transforming protein 3; SHC-transforming protein A; Src homology 2 domain-containing-transforming protein C1; SH2 domain protein C1
WB, IHC-P, ICC/IF, FC
Human, Mouse, Rat
SHC Antibody (YA2394) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SHC.
SD-36 is a potent and efficacious STAT3 PROTAC degrader (Kd=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC50=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase . SD-36 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
SH2B2 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2b3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sh2b3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2b3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sh2b3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B1 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2B3 Human Pre-designed siRNA Set A contains three designed siRNAs for SH2B3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D2A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2d1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sh2d1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sh2d1a Rat Pre-designed siRNA Set A contains three designed siRNAs for Sh2d1a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D4A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D4A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1A Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D1B Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
SH2D3C Human Pre-designed siRNA Set A contains three designed siRNAs for SH2D3C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
